Skip to Main Content

Paper Details

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
Cancer Discov
252
2017
AR, CRPC, Castration-Resistant Prostate Cancer, Mouse, NPp53, NPp53 prostate tumors, NPp53 tumors, PTEN, Pten, SOX11, TP53, Trp53, abiraterone, adenocarcinoma, androgen, androgen receptor, castration-resistant prostate cancer, human, humans, luminal adenocarcinoma, luminal adenocarcinoma cells, mice, mouse, neuroendocrine, patient, patients, tumors
Author NameAffiliation
Elahe A MostaghelClinical Research Division, Fred Hutchinson Cancer Research Center
Andrea CalifanoCenter for Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
Mark A RubinEnglander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weil Cornell Medical College and New York-Presbyterian Hospital
Mark A RubinEnglander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weil Cornell Medical College and New York-Presbyterian Hospital
  • 1 - 4

Datasets

Release 1.2